News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Starpharma Holdings Ltd Partners With Bio-Pharmaceutical Giant AstraZeneca PLC (AZN) To Improve Cancer Treatment


4/7/2014 4:11:51 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Starpharma Holdings (ASX: SPL, OTCQX: SPHRY) has signed a second, expanded agreement with AstraZeneca (NYSE: AZN) in the field of cancer medicine using Starpharma’s proprietary DEP™ dendrimer drug delivery technology.

The agreement follows on from an evaluation by AstraZeneca, which is capped at $81 billion, which began in September 2012 of Starpharma’s delivery technology, and will see the application of Starpharma’s technology to a cancer drug, from AstraZeneca’s pipeline.

Under the new agreement, AstraZeneca will provide funding for a preclinical stage cancer research program to be conducted jointly.

Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses.

Dendrimer-enhanced versions of drugs have been found to be superior to the unmodified drugs in pre-clinical studies, often having improved efficacy and fewer side.

Starpharma’s lead product is VivaGel®, a gel-based formulation of a proprietary dendrimer, under clinical development for the treatment and prevention of bacterial vaginosis.

Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc of Japan to market a value-added, VivaGel® coated condom.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery.

Drug Delivery partners also include global giants GlaxoSmithKline (NYSE:GSK), capped at $126 billion, and Eli Lilly (NYSE:LLY), capped at $67 billion.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES